Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Heeg

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Pharmacoeconomics|December 1, 2007
Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspectiveBart Heeg, Joep Damen, Ben Van Hout
Journal of Comparative Effectiveness Research|December 15, 2023
Improved estimation of overall survival and progression-free survival for state transition modelingPeter C Wigfield, Bart Heeg, Mario Ouwens
Pharmaceutical Statistics|June 15, 2023
Alone, together: On the benefits of Bayesian borrowing in a meta-analytic settingOfir Harari, Mohsen Soltanifar, Andre Verhoek, et al.
Journal of Comparative Effectiveness Research|March 22, 2022
Bridging the gap between oncology clinical trials and real-world data: evidence on replicability of efficacy results using German claims dataMarco Ghiani, Ulf Maywald, Thomas Wilke, et al.
Applied Health Economics and Health Policy|April 23, 2009
A pharmacoeconomic analysis of compliance gains on antipsychotic medicationsJoep Damen, Per-Olof Thuresson, Bart Heeg, et al.
Applied Health Economics and Health Policy|September 1, 2010
Cost effectiveness of long-acting risperidone in SwedenMarja Hensen, Bart Heeg, Mickael Löthgren, et al.
Pharmacoeconomics|March 29, 2025
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic AreasBart Heeg, Dawn Lee, Jane Adam, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Extrapolating Survival Data Using Historical Trial-Based a Priori DistributionsFanni Soikkeli, Mahmoud Hashim, Mario Ouwens, et al.
Pharmacoeconomics|January 19, 2006
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyGerd Laux, Bart Heeg, Ben A van Hout, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 18, 2024
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United StatesPaul Arora, Alind Gupta, Emma Mackay, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Pharmacoeconomics|December 1, 2007
Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspectiveBart Heeg, Joep Damen, Ben Van Hout
Journal of Comparative Effectiveness Research|December 15, 2023
Improved estimation of overall survival and progression-free survival for state transition modelingPeter C Wigfield, Bart Heeg, Mario Ouwens
Pharmaceutical Statistics|June 15, 2023
Alone, together: On the benefits of Bayesian borrowing in a meta-analytic settingOfir Harari, Mohsen Soltanifar, Andre Verhoek, et al.
Journal of Comparative Effectiveness Research|March 22, 2022
Bridging the gap between oncology clinical trials and real-world data: evidence on replicability of efficacy results using German claims dataMarco Ghiani, Ulf Maywald, Thomas Wilke, et al.
Applied Health Economics and Health Policy|April 23, 2009
A pharmacoeconomic analysis of compliance gains on antipsychotic medicationsJoep Damen, Per-Olof Thuresson, Bart Heeg, et al.
Applied Health Economics and Health Policy|September 1, 2010
Cost effectiveness of long-acting risperidone in SwedenMarja Hensen, Bart Heeg, Mickael Löthgren, et al.
Pharmacoeconomics|March 29, 2025
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic AreasBart Heeg, Dawn Lee, Jane Adam, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Extrapolating Survival Data Using Historical Trial-Based a Priori DistributionsFanni Soikkeli, Mahmoud Hashim, Mario Ouwens, et al.
Pharmacoeconomics|January 19, 2006
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyGerd Laux, Bart Heeg, Ben A van Hout, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 18, 2024
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United StatesPaul Arora, Alind Gupta, Emma Mackay, et al.
Pageof 5